Partnership with Nestlé
Artialis selected by Nestlé as premium partner for its clinical research in musculoskeletal disorders
Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine
A review that summarizes current guidance on the use of biomarkers in OA in clinical trials and their utility at five stages, including preclinical development and phase 1 to phase 4 trials. It also presents all the available regulatory requirements.
Meet us at OARSI 2016!
Artialis will be present at the OARSI 2016 World Congress on Osteoarthritis.
Since the biomarker world is very competitive, every work involving new biomarkers should be previously and accurately discussed to tune the interests of the Sponsor with those of Artialis.
They are on time and flexible [and have] the ability to focus rapidly on the Sponsor requirement.
[We appreciate the] reliability of data and the open and timely communication.
Director Pharmacology & Toxicology, Rottapharm Biotech
We needed a specific measure for the cartilage degeneration to prove the efficacy of our product. The collaboration with Artialis was a logical choice
Sales & Marketing Director, Tilman (Belgium)
We wanted to know whether oral treatment with polyphenols could decreased serum level of OA biomarkers in DMM mice model and needed results quickly. [Artialis has offered] robust skills, reactivity, and possibility to academic collaboration.
PhD candidate, INSERM U791, Laboratoire d'Ingénierie Ostéo-Articulaire et Dentaire (France)